Jupiter Neurosciences Inc
Research Jupiter Neurosciences Inc (JUNS) on Bullrun: market cap USD 2.50M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJUNS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.50M
- Financial periodQ1 2026
- RevenueUSD 40.45K
- Net income-USD 2.06M
- Free cash flow-USD 1.43M
- Gross margin35.3%
Valuation Snapshot
latest market cap is USD 2.50M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 21.80K | -USD 8.64M | -USD 5.41M | 80.6% | -0.25 | USD 3.79M | USD 5.32M | -USD 1.83M |
| FY2024 | USD 0 | -USD 2.44M | -USD 3.91M | n/a | -0.08 | USD 3.77M | USD 217.76K | USD 4.17M |
| FY2023 | n/a | -USD 4.78M | n/a | n/a | -0.18 | USD 28.48K | USD 2.25M | -USD 5.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.50M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 33.77M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 354.21M | n/a | n/a | n/a |
About Jupiter Neurosciences Inc
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jupiter Neurosciences Inc's market cap?
Jupiter Neurosciences Inc's market capitalization is USD 2.50M.
What does Jupiter Neurosciences Inc do?
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.